185 related articles for article (PubMed ID: 30095171)
1. Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
Cui F; Hu J; Ning S; Tan J; Tang H
Prostate; 2018 Dec; 78(16):1299-1310. PubMed ID: 30095171
[TBL] [Abstract][Full Text] [Related]
2. Minichromosome maintenance protein 10 as a marker for proliferation and prognosis in lung cancer.
Wang M; Xie S; Yuan W; Xie T; Jamal M; Huang J; Yin Q; Song H; Zhang Q
Int J Oncol; 2019 Dec; 55(6):1349-1360. PubMed ID: 31638210
[TBL] [Abstract][Full Text] [Related]
3. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
4.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
5. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
Huang W; Su X; Yan W; Kong Z; Wang D; Huang Y; Zhai Q; Zhang X; Wu H; Li Y; Li T; Wan X
Prostate; 2018 Dec; 78(16):1248-1261. PubMed ID: 30105831
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
8. MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.
Li WM; Huang CN; Ke HL; Li CC; Wei YC; Yeh HC; Chang LL; Huang CH; Liang PI; Yeh BW; Chan TC; Li CF; Wu WJ
Oncotarget; 2016 Nov; 7(47):77777-77792. PubMed ID: 27780919
[TBL] [Abstract][Full Text] [Related]
9. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.
Lu J; Dong W; He H; Han Z; Zhuo Y; Mo R; Liang Y; Zhu J; Li R; Qu H; Zhang L; Wang S; Ma R; Jia Z; Zhong W
Int J Biol Macromol; 2018 Oct; 118(Pt A):599-609. PubMed ID: 29874556
[TBL] [Abstract][Full Text] [Related]
10. Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.
Zhang H; Shen T; Zhang Z; Li Y; Pan Z
Med Sci Monit; 2019 Aug; 25():6418-6428. PubMed ID: 31451680
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
12. MCM10 facilitates the invaded/migrated potentials of breast cancer cells via Wnt/β-catenin signaling and is positively interlinked with poor prognosis in breast carcinoma.
Yang WD; Wang L
J Biochem Mol Toxicol; 2019 Jul; 33(7):e22330. PubMed ID: 30990947
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation.
Huang Y; Pan XW; Li L; Chen L; Liu X; Lu JL; Zhu XM; Huang H; Yang QW; Ye JQ; Gan SS; Wang LH; Hong Y; Xu DF; Cui XG
Oncotarget; 2016 Apr; 7(16):22016-30. PubMed ID: 26959883
[TBL] [Abstract][Full Text] [Related]
19. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
20. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]